Abstract
Objective: To assess whether the survival of patients with recurrent malignant glioma receiving temozolomide in everyday practice is comparable to that reported in previous studies.
Study design: We conducted a retrospective observational study that included patients with recurrent malignant glioma who where treated with temozolomide.
Patients and methods: The study was based on prospective clinical databases managed by the Italian Local Health Units; the databases are required by Italian Law 648/96 for patients treated with temozolomide before drug approval by the reimbursement agency of the Italian Ministry of Health.
Main outcome measures and results: 201 patients who had received temozolomide during the qualifying period of Law 648/96 for this drug (from 11 March 1998 to 30 September 2000) were included in our study. The clinical indications for temozolomide were glioblastoma multiforme (n = 123), anaplastic astrocytoma (n = 49) or other indications (n = 28). One patient did not have an indication reported. The median survival for patients with glioblastoma multiforme and anaplastic astrocytoma was 13 and 20.3 months, respectively (with survival rates at 6 months of 81% and 78%, respectively).
In our group of 49 patients with anaplastic astrocytoma, the survival plateau observed between 22 and 37 months (with no fatalities over this long time interval) suggested a favourable outcome, although restricted to a small subgroup. The 123 patients with glioblastoma multiforme showed a slightly better survival than that reported previously, but all patients died before 32 months.
Conclusions: This observational study extends the previous information regarding the efficacy of temozolomide and provides survival data from patients treated in everyday practice.
Similar content being viewed by others
References
Dinnes J, Cave C, Huang S, et al. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 2002; 86 (4): 501–5
Macdonald DR. Temozolomide for recurrent high-grade glioma. Semin Oncol 2001; 28 (4 Suppl. 13): 3–12
Stupp R, Gander M, Leyvraz S, et al. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001; 2 (9): 552–60
Conversione in legge del decreto-legge 21 ottobre 1996, n. 536, recante misure per il contenimento della spesa farmaceutica e la rideterminazione del tetto di spesa per l’anno 1996, Legge 23 Dicembre 1996, n. 648, Gazzetta Ufficiale della Repubblica Italiana, 1996, 300
Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12 (2): 259–66
Brandes AA, Ermani M, Basso U, et al. Temozolomide as a second line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol 2001; 12 (2): 255–7
Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000 Sep; 83 (5): 588–93
Yung WK, Prados M, Yaga-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999; 17: 2762–71
Garattini S, Bertele V. Efficacy, safety, and cost of new anti-cancer drugs. BMJ 2002; 325: 269–71
Acknowledgements
There was external no funding for this study, and the authors have no conflicts of interest directly relevant to the content of this study.
The list of study participants includes the study co-ordinators (S. Trippoli, F. Pelagotti, A. Messori, F. Vacca, M. Vaiani, and S. Maltoni from the Laboratorio SIFO di Farmacoeconomia, c/o Azienda Ospedaliera Careggi, Florence, Italy) and the researchers who were responsible for patient recruitment, who are listed here (all from Italy):
M.E. Faggiano, M. Lattarulo, I. Lolli, M. Ronco, G.Troccoli, A. Zecchino (Bari); I. Brucoli, F. Di Cuia, A.Dragone, G. Muschitiello, M. Susi (Matera); M. Di Lieto, P.Tamburini (Pistoia); A. Iop, G. Millevoi (Palmanova); S.Cascinu, N.S. Cieri, G. Ferrari, M.T. Tondelli (Parma); S.Bracarda, A. Ciaccia, C. Pennetta, E. Perrucci, F. Radicchi (Perugia); E. Bini, M.R.Gentili (Ravenna); F. Bennicelli, A.Bernardini (Tortona); A. Di Biasio, C. Di Fabio, P. D’Ovidio, A. Nuzzo (Lanciano, Chieti); C. Lori, M. Rinaldi, (Carrara), C. Bufarini, G. Burroni, A. Paccapelo (Ancona); L. Bordi, C.Menichelli, R. Fornaini, E. Tendi (Firenze); S. Bartolini, L.Crinò, V. Gioia, G. Sangiorgi Cellini (Bologna).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trippoli, S., Pelagotti, F., Messori, A. et al. Survival of Patients with Recurrent Malignant Glioma Treated with Temozolomide. Drugs R&D 4, 285–291 (2003). https://doi.org/10.2165/00126839-200304050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200304050-00002